(Abst.) 6-year safety and efficacy outcomes w/first-line ofatumumab in recently diagnosed pts. w/relapsing MS on: December 12, 2025, 09:13:17 pm #1 From PubMed (December 12, 2025)--"Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis": Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis - PubMed Findings support ofatumumab's highly favourable longer-term benefit-risk profile as first-line therapy for plwRMS. PubMed · pubmed.ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
